Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | MST1R | Q04912 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989991 | 0.92 | JAK2 (0.31) | JAK2JAK3BRD4CREBBP | |
| SCHEMBL20706409 | 0.91 | AURKA (0.35) | AURKADAPK3JAK2ROCK2PAK4 | |
| SCHEMBL9989855 | 0.88 | — | — | |
| SCHEMBL9990213 | 0.86 | — | — | |
| SCHEMBL9989870 | 0.86 | — | — | |
| SCHEMBL15203409 | 0.86 | BRD4 (0.30) | BRD4CREBBP | |
| SCHEMBL15203412 | 0.84 | — | — | |
| SCHEMBL9992207 | 0.82 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL1933815 | 0.82 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL9989840 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | AURKA 1637/4885DAPK3 2756/4885JAK2 356/4885 |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | AURKA 1637/4885DAPK3 2756/4885JAK2 356/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | AURKA 1637/4885DAPK3 2756/4885JAK2 356/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | AURKA 1637/4885DAPK3 2756/4885JAK2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.